ID   GIST430
AC   CVCL_7040
SY   GIST-430; GIST 430
DR   cancercelllines; CVCL_7040
DR   ChEMBL-Cells; CHEMBL4482996
DR   ChEMBL-Targets; CHEMBL4483237
DR   Cosmic; 1180674
DR   Cosmic; 1873951
DR   GEO; GSM486233
DR   GEO; GSM2527256
DR   GEO; GSM2527257
DR   GEO; GSM2786735
DR   Progenetix; CVCL_7040
DR   PubChem_Cell_line; CVCL_7040
DR   Wikidata; Q54835857
RX   PubMed=16954519;
RX   PubMed=16982758;
RX   PubMed=22665524;
RX   PubMed=25239608;
RX   PubMed=29866822;
RX   PubMed=30488756;
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Val560_Leu576del (c.1678_1728del); ClinVar=VCV000523644; Zygosity=Heterozygous (PubMed=16954519; PubMed=16982758; PubMed=25239608).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Val654Ala (c.1961T>C); ClinVar=VCV000375921; Zygosity=Heterozygous (PubMed=16954519; PubMed=16982758; PubMed=25239608).
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Cell type: Interstitial cell of Cajal; CL=CL_0002088.
DI   NCIt; C3868; Gastrointestinal stromal tumor
DI   ORDO; Orphanet_44890; Gastrointestinal stromal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=16954519; DOI=10.1200/JCO.2006.06.2265;
RA   Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H.,
RA   Roberts P.J., Eisenberg B.L., von Mehren M., Fletcher C.D.M., Sandau K.,
RA   McDougall K., Ou W.-B., Chen C.-J., Fletcher J.A.;
RT   "Molecular correlates of imatinib resistance in gastrointestinal
RT   stromal tumors.";
RL   J. Clin. Oncol. 24:4764-4774(2006).
//
RX   PubMed=16982758; DOI=10.1158/0008-5472.CAN-06-0165;
RA   Bauer S., Yu L.K., Demetri G.D., Fletcher J.A.;
RT   "Heat shock protein 90 inhibition in imatinib-resistant
RT   gastrointestinal stromal tumor.";
RL   Cancer Res. 66:9153-9161(2006).
//
RX   PubMed=22665524; DOI=10.1158/1535-7163.MCT-12-0223; PMCID=PMC3992122;
RA   Heinrich M.C., Marino-Enriquez A., Presnell A., Donsky R.S.,
RA   Griffith D.J., McKinley A., Patterson J., Taguchi T., Liang C.-W.,
RA   Fletcher J.A.;
RT   "Sorafenib inhibits many kinase mutations associated with
RT   drug-resistant gastrointestinal stromal tumors.";
RL   Mol. Cancer Ther. 11:1770-1780(2012).
//
RX   PubMed=25239608; DOI=10.1158/1078-0432.CCR-14-1397; PMCID=PMC4233175;
RA   Garner A.P., Gozgit J.M., Anjum R., Vodala S., Schrock A.B., Zhou T.-J.,
RA   Serrano C., Eilers G., Zhu M.-J., Ketzer J., Wardwell S., Ning Y.,
RA   Song Y., Kohlmann A., Wang F., Clackson T., Heinrich M.C.,
RA   Fletcher J.A., Bauer S., Rivera V.M.;
RT   "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and
RT   shows therapeutic potential in heavily pretreated gastrointestinal
RT   stromal tumor (GIST) patients.";
RL   Clin. Cancer Res. 20:5745-5755(2014).
//
RX   PubMed=29866822; DOI=10.1073/pnas.1802079115; PMCID=PMC6016782;
RA   Hemming M.L., Lawlor M.A., Zeid R., Lesluyes T., Fletcher J.A.,
RA   Raut C.P., Sicinska E.T., Chibon F., Armstrong S.A., Demetri G.D.,
RA   Bradner J.E.;
RT   "Gastrointestinal stromal tumor enhancers support a transcription
RT   factor network predictive of clinical outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E5746-E5755(2018).
//
RX   PubMed=30488756; DOI=10.1080/15384101.2018.1553335; PMCID=PMC6300111;
RA   Tu Y.-Q., Zuo R., Ni N., Eilers G., Wu D.-L., Pei Y.-T., Nie Z.-M.,
RA   Wu Y.-Q., Wu Y.-H., Ou W.-B.;
RT   "Activated tyrosine kinases in gastrointestinal stromal tumor with
RT   loss of KIT oncoprotein expression.";
RL   Cell Cycle 17:2577-2592(2018).
//